Entresto 200 mg 102.8 mg, 97.2 mg Jordan - engelsk - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

entresto 200 mg 102.8 mg, 97.2 mg

شركة مستودع الأدوية الأردني - the jordan drugstore co - valsartan 102.8 mg, sacubitril 97.2 mg - 102.8 mg, 97.2 mg

Sandostatin 100 mcg/ml Solution for Injection Jordan - engelsk - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

sandostatin 100 mcg/ml solution for injection

شركة مستودع الأدوية الأردني - the jordan drugstore co - octreotide 100 mcg/ml - 100 mcg/ml

Seroxat Tab 20 mg Jordan - engelsk - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

seroxat tab 20 mg

مستودع أدوية سليمان طنوس وأولاده - suleiman tannous & sons co. ltd - paroxetine 20 mg - 20 mg

SKYRIZI 150 MG Israel - engelsk - Ministry of Health

skyrizi 150 mg

abbvie biopharmaceuticals ltd, israel - risankizumab - solution for injection - risankizumab 150 mg / 1 ml - risankizumab - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who arecandidates for systemic therapy.psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of activepsoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards).

Lipanthyl 200 mg Jordan - engelsk - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

lipanthyl 200 mg

مستودع أدوية أبوشيخة - abu sheikha drug store - fenofibrate 200 mg - 200 mg

ROSUVASTATIN SANDOZ 10 MG Israel - engelsk - Ministry of Health

rosuvastatin sandoz 10 mg

novartis israel ltd - rosuvastatin as calcium - film coated tablets - rosuvastatin as calcium 10 mg - rosuvastatin - primary hypercholesterolaemia (type iia including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type iib) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction) is inadequate. homozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. ldl apheresis) or if such treatments are not appropriate.